Is Pfizer's new R&D plan doomed to failure?

Pfizer garnered headlines recently when it announced plans to launch a new innovation center that will create teams of academic and pharma researchers in the Boston area, one of the world's hottest biotech hubs. Xconomy's Luke Timmerman talked with one of the principals, and came away highly doubtful of the project's success. Academia and pharma have radically different cultures, he maintains, which rarely work well together. But if it is a success, Pfizer can get up to 30 percent of its early-stage work done through the program and just might create a whole new R&D template for the field. Story

Suggested Articles

Versantis will use the €16 million to trial a drug designed to remove toxic metabolites from liver disease patients.

The Merck-backed round positions Themis to take its chikungunya vaccine through phase 3 and start testing a cancer drug in humans.

No biohazardous substances were in the room where the explosion happened, according to the Russian virology center.